Terns Pharmaceuticals announced that the FDA granted orphan drug designation for TERN-701 for the treatment of chronic myeloid leukemia, or CML. TERN-701, the company’s internally discovered allosteric BCR-ABL tyrosine kinase inhibitor, is in Phase 1 clinical development with interim data from initial dose escalation cohorts expected in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TERN:
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns treatment of chronic myelogenous leukemia granted orphan status
- Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Terns Pharmaceuticals Welcomes New CEO and Board Member
